| Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference P Wallemacq, VW Armstrong, M Brunet, V Haufroid, DW Holt, A Johnston, ... Therapeutic drug monitoring 31 (2), 139-152, 2009 | 544 | 2009 |
| Type of PKD1 mutation influences renal outcome in ADPKD E Cornec-Le Gall, MP Audrézet, JM Chen, M Hourmant, MP Morin, ... Journal of the American Society of Nephrology 24 (6), 1006-1013, 2013 | 536 | 2013 |
| Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation Y Le Meur, M Büchler, A Thierry, S Caillard, F Villemain, S Lavaud, ... American Journal of Transplantation 7 (11), 2496-2503, 2007 | 487 | 2007 |
| Mutations in GANAB, encoding the glucosidase IIα subunit, cause autosomal-dominant polycystic kidney and liver disease B Porath, VG Gainullin, E Cornec-Le Gall, EK Dillinger, CM Heyer, ... The American Journal of Human Genetics 98 (6), 1193-1207, 2016 | 472* | 2016 |
| Optimization of initial tacrolimus dose using pharmacogenetic testing E Thervet, MA Loriot, S Barbier, M Buchler, M Ficheux, G Choukroun, ... Clinical Pharmacology & Therapeutics 87 (6), 721-726, 2010 | 411 | 2010 |
| Consensus report on therapeutic drug monitoring of mycophenolic acid in solid organ transplantation DRJ Kuypers, Y Le Meur, M Cantarovich, MJ Tredger, SE Tett, D Cattaneo, ... Clinical journal of the American Society of Nephrology 5 (2), 341-358, 2010 | 367 | 2010 |
| The PROPKD score: a new algorithm to predict renal survival in autosomal dominant polycystic kidney disease E Cornec-Le Gall, MP Audrézet, A Rousseau, M Hourmant, ... Journal of the American Society of Nephrology 27 (3), 942-951, 2016 | 363 | 2016 |
| Identification of the UDP-glucuronosyltransferase isoforms involved in mycophenolic acid phase II metabolism N Picard, D Ratanasavanh, A Prémaud, Y Le Meur, P Marquet Drug metabolism and disposition 33 (1), 139-146, 2005 | 334 | 2005 |
| Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney … RT Gansevoort, M Arici, T Benzing, H Birn, G Capasso, A Covic, ... Nephrology Dialysis Transplantation 31 (3), 337-348, 2016 | 322 | 2016 |
| Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study Y Lebranchu, A Thierry, O Toupance, PF Westeel, I Etienne, E Thervet, ... American Journal of Transplantation 9 (5), 1115-1123, 2009 | 304 | 2009 |
| Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy Y Lebranchu, F Bridoux, M Büchler, Y Le Meur, I Etienne, O Toupance, ... American Journal of Transplantation 2 (1), 48-56, 2002 | 294 | 2002 |
| Monoallelic mutations to DNAJB11 cause atypical autosomal-dominant polycystic kidney disease E Cornec-Le Gall, RJ Olson, W Besse, CM Heyer, VG Gainullin, JM Smith, ... The American Journal of Human Genetics 102 (5), 832-844, 2018 | 284 | 2018 |
| An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants S Caillard, D Anglicheau, M Matignon, A Durrbach, C Greze, L Frimat, ... Kidney international 98 (6), 1549-1558, 2020 | 266 | 2020 |
| CYP3A5 and MDR1 Genetic Polymorphisms and Cyclosporine Pharmacokinetics After Renal Transplantation D Anglicheau, E Thervet, I Etienne, B Hurault De Ligny, Y Le Meur, ... Clinical Pharmacology & Therapeutics 75 (5), 422-433, 2004 | 253 | 2004 |
| Is COVID‐19 infection more severe in kidney transplant recipients? S Caillard, N Chavarot, H Francois, M Matignon, C Greze, N Kamar, ... American Journal of Transplantation 21 (3), 1295-1303, 2021 | 242 | 2021 |
| Sirolimus versus cyclosporine in kidney recipients receiving Thymoglobulin®, mycophenolate mofetil and a 6‐month course of steroids M Büchler, S Caillard, S Barbier, E Thervet, O Toupance, H Mazouz, ... American Journal of Transplantation 7 (11), 2522-2531, 2007 | 200 | 2007 |
| The role of organic anion–transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics N Picard, SW Yee, JB Woillard, Y Lebranchu, Y Le Meur, KM Giacomini, ... Clinical Pharmacology & Therapeutics 87 (1), 100-108, 2010 | 195 | 2010 |
| Tacrolimus population pharmacokinetic-pharmacogenetic analysis and Bayesian estimation in renal transplant recipients K Benkali, A Prémaud, N Picard, JP Rérolle, O Toupance, G Hoizey, ... Clinical pharmacokinetics 48, 805-816, 2009 | 162 | 2009 |
| B-Cells induce regulatory T cells through TGF-β/IDO production in A CTLA-4 dependent manner A Nouel, P Pochard, Q Simon, I Segalen, Y Le Meur, JO Pers, S Hillion Journal of autoimmunity 59, 53-60, 2015 | 153 | 2015 |
| Correction of postkidney transplant anemia reduces progression of allograft nephropathy G Choukroun, N Kamar, B Dussol, I Etienne, E Cassuto-Viguier, ... Journal of the American Society of Nephrology 23 (2), 360-368, 2012 | 153 | 2012 |
